Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease

Current Medicinal Chemistry

Volumn 20, Issue 12, 2013, Pages 1496-1530

  Biswas, S ^a   Hwang, J W ^b   Kirkham, P A ^c   Rahman, I ^b  

^a Dr Ambedkar College   (India)

^b UNIVERSITY OF ROCHESTER   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Antioxidants; Biomarkers; Chronic obstructive pulmonary disease; Cigarette smoke; Glutathione; Inflammation; Lipid peroxidation; Natural products; Nrf2; Oxidants; Polyphenols; Protein carbonylation; Redox; Smokers; Thiols

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; BETA CAROTENE; CARBOCISTEINE; CARBONYL DERIVATIVE; CIGARETTE SMOKE; CURCUMIN; CYSTEINE DERIVATIVE; ERDOSTEINE; FREE RADICAL; FUDOSTEINE; GLUTAREDOXIN; HISTONE DEACETYLASE 2; LAZAROID; LYSINE DERIVATIVE; MC 186; N ACYSTELYN; N ISOBUTYRYLCYSTEINE; NORPHENAZONE; PEROXIREDOXIN; PLACEBO; POLYPHENOL DERIVATIVE; RESVERATROL; THIOL DERIVATIVE; THIONEINE; THIOREDOXIN; TIRILAZAD; TRANSCRIPTION FACTOR NRF2; U 75412E; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AIR POLLUTION; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CATALYST; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HUMAN; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN CARBONYLATION; SENSOR; SMOKING CESSATION; SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; FREE RADICALS; HUMANS; LIPID PEROXIDATION; LUNG; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE; TOBACCO;

EID: 84877960872     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320120004     Document Type: Article

References (372)

1. Rahman, I.; Marwick, J.; Kirkham, P., Redox modulation of chromatin remodeling: Impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem. Pharmacol., 2004, 68 (6), 1255-1267.
2. Yao, H.; Rahman, I., Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol. Appl. Pharmacol., 2011, 254 (2), 72-85.
3. Biswas, S.K.; Rahman, I., Environmental toxicity, redox signaling and lung inflammation: The role of glutathione. Mol. Aspects. Med., 2009, 30 (1-2), 60-76.
4. Rahman, I., Antioxidant therapeutic advances in COPD. Ther. Adv. Respir. Dis., 2008, 2 (6), 351-374.
5. Rahman, I., Antioxidant therapies in COPD. Int. J. Chron. Obstruct. Pulmon. Dis., 2006, 1 (1), 15-29.
6. Rahman, I.; Adcock, I.M., Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J., 2006, 28 (1), 219-242.
7. Rahman, I., Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim. Biophys. Acta., 2012, 1822 (5), 714-728.
8. Makita, H.; Nasuhara, Y.; Nagai, K.; Ito, Y.; Hasegawa, M.; Betsuyaku, T.; Onodera, Y.; Hizawa, N.; Nishimura, M., Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax, 2007, 62 (11), 932-937.
9. Patel, B.; Make, B.; Coxson, H.O.; Muller, N.L.; Pillai, S.; Anderson, W.; Silverman, E.; Lomas, D., Airway and parenchymal disease in chronic obstructive pulmonary disease are distinct phenotypes. Proc. Am. Thorac. Soc., 2006, 3 (6), 533.
10. Gompertz, S.; Bayley, D.L.; Hill, S.L.; Stockley, R.A., Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax, 2001, 56 (1), 36-41.
11. Pinamonti, S.; Leis, M.; Barbieri, A.; Leoni, D.; Muzzoli, M.; Sostero, S.; Chicca, M.C.; Carrieri, A.; Ravenna, F.; Fabbri, L.M.; Ciaccia, A., Detection of xanthine oxidase activity products by EPR and HPLC in bronchoalveolar lavage fluid from patients with chronic obstructive pulmonary disease. Free Radic. Biol. Med., 1998, 25 (7), 771-779.
12. Bindoli, A.; Fukuto, J.M.; Forman, H.J., Thiol chemistry in peroxidase catalysis and redox signaling. Antioxid. Redox. Signal., 2008, 10 (9), 1549-1564.
13. Aaron, S.D.; Angel, J.B.; Lunau, M.; Wright, K.; Fex, C.; Le Saux, N.; Dales, R.E., Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2001, 163 (2), 349-355.
14. Church, D.F.; Pryor, W.A., Free-radical chemistry of cigarette smoke and its toxicological implications. Environ. Health Perspect., 1985, 64, 111-126.
15. Nakayama, T.; Church, D.F.; Pryor, W.A., Quantitative analysis of the hydrogen peroxide formed in aqueous cigarette tar extracts. Free Radic. Biol. Med., 1989, 7 (1), 9-15.
16. Pryor, W.A.; Stone, K., Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann. N. Y. Acad. Sci., 1993, 686, 12-27.
17. Caramori, G.; Adcock, I.M.; Casolari, P.; Ito, K.; Jazrawi, E.; Tsaprouni, L.; Villetti, G.; Civelli, M.; Carnini, C.; Chung, K.F.; Barnes, P.J.; Papi, A., Unbalanced oxidant-induced DNA damage and repair in COPD: A link towards lung cancer. Thorax, 2011, 66 (6), 521-527.
18. Montuschi, P.; Collins, J.V.; Ciabattoni, G.; Lazzeri, N.; Corradi, M.; Kharitonov, S.A.; Barnes, P.J., Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med., 2000, 162 (3 Pt 1), 1175-1177.
19. Rahman, I.; van Schadewijk, A.A.; Crowther, A.J.; Hiemstra, P.S.; Stolk, J.; MacNee, W.; De Boer, W.I., 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2002, 166 (4), 490-495.
20. Seet, R.C.; Lee, C.Y.; Loke, W.M.; Huang, S.H.; Huang, H.; Looi, W.F.; Chew, E.S.; Quek, A.M.; Lim, E.C.; Halliwell, B., Biomarkers of oxidative damage in cigarette smokers: Which biomarkers might reflect acute versus chronic oxidative stress? Free Radic. Biol. Med., 2011, 50 (12), 1787-1793.
21. Moretto, N.; Facchinetti, F.; Southworth, T.; Civelli, M.; Singh, D.; Patacchini, R., alpha,beta-Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases. Am. J. Physiol. Lung Cell Mol. Physiol., 2009, 296 (5), L839-848.
22. Dalle-Donne, I.; Giustarini, D.; Colombo, R.; Rossi, R.; Milzani, A., Protein carbonylation in human diseases. Trends Mol. Med., 2003, 9 (4), 169-176.
23. Cloos, P.A.; Christgau, S., Post-translational modifications of proteins: Implications for aging, antigen recognition, and autoimmunity. Biogerontology, 2004, 5 (3), 139-158.
24. Negre-Salvayre, A.; Coatrieux, C.; Ingueneau, C.; Salvayre, R., Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br. J. Pharmacol., 2008, 153 (1), 6-20.
25. Dalle-Donne, I.; Aldini, G.; Carini, M.; Colombo, R.; Rossi, R.; Milzani, A., Protein carbonylation, cellular dysfunction, and disease progression. J. Cell Mol. Med., 2006, 10 (2), 389-406.
26. Grimsrud, P.A.; Xie, H.; Griffin, T.J.; Bernlohr, D.A., Oxidative stress and covalent modification of protein with bioactive aldehydes. J. Biol. Chem., 2008, 283 (32), 21837-21841.
27. Thornalley, P.J., Pharmacology of methylglyoxal: Formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol., 1996, 27 (4), 565-573.
28. Reznick, A.Z.; Cross, C.E.; Hu, M.L.; Suzuki, Y.J.; Khwaja, S.; Safadi, A.; Motchnik, P.A.; Packer, L.; Halliwell, B., Modification of plasma proteins by cigarette smoke as measured by protein carbonyl formation. Biochem. J., 1992, 286 (Pt 2), 607-611.
29. Aldini, G.; Dalle-Donne, I.; Colombo, R.; Maffei Facino, R.; Milzani, A.; Carini, M., Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction. ChemMedChem, 2006, 1 (10), 1045-1058.
30. Kirkham, P.A.; Caramori, G.; Casolari, P.; Papi, A.A.; Edwards, M.; Shamji, B.; Triantaphyllopoulos, K.; Hussain, F.; Pinart, M.; Khan, Y.; Heinemann, L.; Stevens, L.; Yeadon, M.; Barnes, P.J.; Chung, K.F.; Adcock, I.M., Oxidative Stress-induced Antibodies to Carbonyl-modified Protein Correlate with Severity of Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med., 2011, 184 (7), 796-802.
31. Groeger, A.L.; Freeman, B.A., Signaling actions of electrophiles: Anti-inflammatory therapeutic candidates. Mol. Interv., 2010, 10 (1), 39-50.
32. Kirkham, P.A.; Spooner, G.; Ffoulkes-Jones, C.; Calvez, R., Cigarette smoke triggers macrophage adhesion and activation: Role of lipid peroxidation products and scavenger receptor. Free Radic. Biol. Med., 2003, 35 (7), 697-710.
33. Kirkham, P.A.; Spooner, G.; Rahman, I.; Rossi, A.G., Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke and lipid peroxidation products. Biochem. Biophys. Res. Commun., 2004, 318 (1), 32-37.
34. Kluchova, Z.; Petrasova, D.; Joppa, P.; Dorkova, Z.; Tkacova, R., The association between oxidative stress and obstructive lung impairment in patients with COPD. Physiol. Res., 2007, 56 (1), 51-56.
35. Yang, S.R.; Chida, A.S.; Bauter, M.R.; Shafiq, N.; Seweryniak, K.; Maggirwar, S.B.; Kilty, I.; Rahman, I., Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am. J. Physiol. Lung Cell Mol. Physiol., 2006, 291 (1), L46-57.
36. Caito, S.; Rajendrasozhan, S.; Cook, S.; Chung, S.; Yao, H.; Friedman, A.E.; Brookes, P.S.; Rahman, I., SIRT1 is a redoxsensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. FASEB J., 2010, 24 (9), 3145-3159.
37. Kurien, B.T.; Scofield, R.H., Autoimmunity and oxidatively modified autoantigens. Autoimmun. Rev., 2008, 7 (7), 567-573.
38. Rahman, I.; Morrison, D.; Donaldson, K.; MacNee, W., Systemic oxidative stress in asthma, COPD, and smokers. Am. J. Respir. Crit. Care Med., 1996, 154 (4 Pt 1), 1055-1060.
39. Rahman, I.; Swarska, E.; Henry, M.; Stolk, J.; MacNee, W., Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease? Thorax, 2000, 55 (3), 189-193.
40. Rahman, I.; MacNee, W., Regulation of redox glutathione levels and gene transcription in lung inflammation: Therapeutic approaches. Free Radic. Biol. Med., 2000, 28 (9), 1405-1420.
41. Nicks, M.E.; O'Brien, M.M.; Bowler, R.P., Plasma Antioxidants Are Associated with Impaired Lung Function and COPD Exacerbations in Smokers. COPD, 2011, 8 (4), 264-269.
42. Garbin, U.; Fratta Pasini, A.; Stranieri, C.; Cominacini, M.; Pasini, A.; Manfro, S.; Lugoboni, F.; Mozzini, C.; Guidi, G.; Faccini, G.; Cominacini, L., Cigarette smoking blocks the protective expression of Nrf2/ARE pathway in peripheral mononuclear cells of young heavy smokers favouring inflammation. PLoS One, 2009, 4 (12), e8225.
43. Gould, N.S.; Min, E.; Gauthier, S.; Chu, H.W.; Martin, R.; Day, B.J., Aging adversely affects the cigarette smoke-induced glutathione adaptive response in the lung. Am. J. Respir. Crit. Care Med., 2010, 182 (9), 1114-1122.
44. Sehlstedt, M.; Dove, R.; Boman, C.; Pagels, J.; Swietlicki, E.; Londahl, J.; Westerholm, R.; Bosson, J.; Barath, S.; Behndig, A.F.; Pourazar, J.; Sandstrom, T.; Mudway, I.S.; Blomberg, A., Antioxidant airway responses following experimental exposure to wood smoke in man. Part Fibre Toxicol., 2010, 7, 21.
45. Barreiro, E.; Peinado, V.I.; Galdiz, J.B.; Ferrer, E.; Marin-Corral, J.; Sanchez, F.; Gea, J.; Barbera, J.A., Cigarette smoke-induced oxidative stress: A role in chronic obstructive pulmonary disease skeletal muscle dysfunction. Am. J. Respir. Crit. Care Med., 2010, 182 (4), 477-488.
46. Wu, W.; Patel, K.B.; Booth, J.L.; Zhang, W.; Metcalf, J.P., Cigarette smoke extract suppresses the RIG-I-initiated innate immune response to influenza virus in the human lung. Am. J. Physiol. Lung Cell Mol. Physiol., 2011, 300 (6), L821-830.
47. McGrath-Morrow, S.; Malhotra, D.; Lauer, T.; Michael Collaco, J.; Mitzner, W.; Neptune, E.; Wise, R.; Biswal, S., Exposure to neonatal cigarette smoke causes durable lung changes but does not potentiate cigarette smoke-induced chronic obstructive pulmonary disease in adult mice. Exp. Lung Res., 2011, 37, (6), 354-363.
48. Rahman, I.; Biswas, S.K.; Kode, A., Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol, 2006, 533, (1-3), 222-239.
49. Decramer, M.; Dekhuijzen, P.N.; Troosters, T.; van Herwaarden, C.; Rutten-van Molken, M.; van Schayck, C.P.; Olivieri, D.; Lankhorst, I.; Ardia, A., The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): Hypothesis and design. BRONCUS-trial Committee. Eur Respir J, 2001, 17, (3), 329-336.
50. Decramer, M.; Rutten-van Molken, M.; Dekhuijzen, P.N.; Troosters, T.; van Herwaarden, C.; Pellegrino, R.; van Schayck, C.P.; Olivieri, D.; Del Donno, M.; De Backer, W.; Lankhorst, I.; Ardia, A., Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet, 2005, 365, (9470), 1552-1560.
51. Poole, P.J.; Black, P.N., Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: Systematic review. BMJ, 2001, 322, (7297), 1271-1274.
52. Poole, P.J.; Black, P.N., Preventing exacerbations of chronic bronchitis and COPD: Therapeutic potential of mucolytic agents. Am J Respir Med, 2003, 2, (5), 367-370.
53. Stey, C.; Steurer, J.; Bachmann, S.; Medici, T.C.; Tramer, M.R., The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review. Eur Respir J, 2000, 16, (2), 253-262.
54. Grandjean, E.M.; Berthet, P.; Ruffmann, R.; Leuenberger, P., Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published doubleblind, placebo-controlled clinical trials. Clin Ther, 2000, 22, (2), 209-221.
55. Bridgeman, M.M.; Marsden, M.; Selby, C.; Morrison, D.; MacNee, W., Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax, 1994, 49, (7), 670-675.
56. Kasielski, M.; Nowak, D., Long-term administration of Nacetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med, 2001, 95, (6), 448-456.
57. Black, P.N.; Morgan-Day, A.; McMillan, T.E.; Poole, P.J.; Young, R.P., Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC Pulm Med, 2004, 4, 13.
58. van Overveld, F.J.; Demkow, U.; Gorecka, D.; de Backer, W.A.; Zielinski, J., New developments in the treatment of COPD: Comparing the effects of inhaled corticosteroids and Nacetylcysteine. J Physiol Pharmacol, 2005, 56, 135-142.
59. De Benedetto, F.; Aceto, A.; Dragani, B.; Spacone, A.; Formisano, S.; Pela, R.; Donner, C.F.; Sanguinetti, C.M., Long-term oral nacetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther, 2005, 18, (1), 41-47.
60. Moretti, M.; Bottrighi, P.; Dallari, R.; Da Porto, R.; Dolcetti, A.; Grandi, P.; Garuti, G.; Guffanti, E.; Roversi, P.; De Gugliemo, M.; Potena, A., The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: The EQUALIFE Study. Drugs Exp Clin Res, 2004, 30, (4), 143-152.
61. Zheng, J.P.; Kang, J.; Huang, S.G.; Chen, P.; Yao, W.Z.; Yang, L.; Bai, C.X.; Wang, C.Z.; Wang, C.; Chen, B.Y.; Shi, Y.; Liu, C.T.; Li, Q.; Wang, Z.S.; Huang, Y.J.; Luo, Z.Y.; Chen, F.P.; Yuan, J.Z.; Yuan, B.T.; Qian, H.P.; Zhi, R.C.; Zhong, N.S., Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): A randomised placebocontrolled study. Lancet, 2008, 371, (9629), 2013-2018.
62. Rubio, M.L.; Martin-Mosquero, M.C.; Ortega, M.; Peces-Barba, G.; Gonzalez-Mangado, N., Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest, 2004, 125, (4), 1500-1506.
63. Alam, S.; Li, Z.; Janciauskiene, S.; Mahadeva, R., Oxidation of Z alpha1-antitrypsin by cigarette smoke induces polymerization: A novel mechanism of early-onset emphysema. Am. J. Respir. Cell Mol. Biol., 2011, 45, (2), 261-269.
64. Chung, S.; Sundar, I.K.; Yao, H.; Ho, Y.S.; Rahman, I., Glutaredoxin 1 regulates cigarette smoke-mediated lung inflammation through differential modulation of I{kappa}B kinases in mice: Impact on histone acetylation. Am J Physiol Lung Cell Mol Physiol, 2010, 299, (2), L192-203.
65. Dekhuijzen, P.N., Antioxidant properties of N-acetylcysteine: Their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J, 2004, 23, (4), 629-636.
66. Van Schooten, F.J.; Besaratinia, A.; De Flora, S.; D'Agostini, F.; Izzotti, A.; Camoirano, A.; Balm, A.J.; Dallinga, J.W.; Bast, A.; Haenen, G.R.; Van't Veer, L.; Baas, P.; Sakai, H.; Van Zandwijk, N., Effects of oral administration of N-acetyl-L-cysteine: A multibiomarker study in smokers. Cancer Epidemiol Biomarkers Prev, 2002, 11, (2), 167-175.
67. Koechlin, C.; Couillard, A.; Cristol, J.P.; Chanez, P.; Hayot, M.; Le Gallais, D.; Prefaut, C., Does systemic inflammation trigger local exercise-induced oxidative stress in COPD? Eur Respir J, 2004, 23, (4), 538-544.
68. Dueholm, M.; Nielsen, C.; Thorshauge, H.; Evald, T.; Hansen, N.C.; Madsen, H.D.; Maltbaek, N., N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: A multi-centre study. Respir Med, 1992, 86, (2), 89-92.
69. Gerrits, C.M.; Herings, R.M.; Leufkens, H.G.; Lammers, J.W., Nacetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J, 2003, 21, (5), 795-798.
70. Gillissen, A.; Jaworska, M.; Orth, M.; Coffiner, M.; Maes, P.; App, E.M.; Cantin, A.M.; Schultze-Werninghaus, G., Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir Med, 1997, 91, (3), 159-168.
71. Hardy, J.G.; Newman, S.P.; Knoch, M., Lung deposition from four nebulizers. Respir Med, 1993, 87, (6), 461-465.
72. Guidot, D.M.; Brown, L.A., Mitochondrial glutathione replacement restores surfactant synthesis and secretion in alveolar epithelial cells of ethanol-fed rats. Alcohol Clin Exp Res, 2000, 24, (7), 1070-1076.
73. Hodge, S.; Matthews, G.; Mukaro, V.; Ahern, J.; Shivam, A.; Hodge, G.; Holmes, M.; Jersmann, H.; Reynolds, P.N., Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. Am. J. Respir. Cell Mol. Biol., 2011, 44, (5), 673-681.
74. Butterworth, M.; Upshall, D.G.; Hobbs, M.; Cohen, G.M., Elevation of cysteine and replenishment of glutathione in rat lung slices by cysteine isopropylester and other cysteine precursors. Biochem Pharmacol, 1993, 45, (9), 1769-1774.
75. Paromov, V.; Kumari, S.; Brannon, M.; Kanaparthy, N.S.; Yang, H.; Smith, M.G.; Stone, W.L., Protective effect of liposomeencapsulated glutathione in a human epidermal model exposed to a mustard gas analog. J Toxicol, 2011, 2011, 109516.
76. Ekberg-Jansson, A.; Larson, M.; MacNee, W.; Tunek, A.; Wahlgren, L.; Wouters, E.F.; Larsson, S., N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur Respir J, 1999, 13, (4), 829-834.
77. Moretti, M., Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev Respir Med, 2007, 1, (3), 307-316.
78. Moretti, M., Erdosteine: Its relevance in COPD treatment. Expert Opin Drug Metab Toxicol, 2009, 5, (3), 333-343.
79. Cazzola, M.; Floriani, I.; Page, C.P., The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: A meta-analysis of individual patient data. Pulm Pharmacol Ther, 2010, 23, (2), 135-144.
80. Dal Negro, R.W., Erdosteine: Antitussive and anti-inflammatory effects. Lung, 2008, 186 Suppl 1, S70-73.
81. Dal Negro, R.W.; Visconti, M.; Tognella, S.; Micheletto, C., Erdosteine affects eicosanoid production in COPD. Int J Clin Pharmacol Ther, 2011, 49, (1), 41-45.
82. Braga, P.C.; Allegra, L.; Rampoldi, C.; Ornaghi, A.; Beghi, G., Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteinelysine to patients with chronic bronchitis. Respiration, 1990, 57, (6), 353-358.
83. Carpagnano, G.E.; Resta, O.; Foschino-Barbaro, M.P.; Spanevello, A.; Stefano, A.; Di Gioia, G.; Serviddio, G.; Gramiccioni, E., Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: Effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol, 2004, 505, (1-3), 169-175.
84. Hanaoka, M.; Droma, Y.; Chen, Y.; Agatsuma, T.; Kitaguchi, Y.; Voelkel, N.F.; Kubo, K., Carbocisteine protects against emphysema induced by cigarette smoke extract in rats. Chest, 2011, 139, (5), 1101-1108.
85. Asti, C.; Melillo, G.; Caselli, G.F.; Daffonchio, L.; Hernandez, A.; Clavenna, G.; Omini, C., Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness. Pharmacol Res, 1995, 31, (6), 387-392.
86. Ishibashi, Y.; Okamura, T.; Masumoto, Y.; Tachiiri, T.; Momo, K., [Effects of carbocisteine on airway inflammation and related events in SO2-exposed rats]. Nihon Kokyuki Gakkai Zasshi, 2001, 39, (1), 17-23.
87. Zheng, C.H.; Ahmed, K.; Rikitomi, N.; Martinez, G.; Nagatake, T., The effects of Sβcarboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol, 1999, 43, (2), 107-113.
88. Cakan, G.; Turkoz, M.; Turan, T.; Ahmed, K.; Nagatake, T., Scarboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells. Microb Pathog, 2003, 34, (6), 261-265.
89. Tatsumi, K.; Fukuchi, Y., Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc, 2007, 55, (11), 1884-1886.
90. Aylward, M., An assessment of Sβcarboxymethylcysteine in the treatment of chronic bronchitis. Curr Med Res Opin, 1974, 2, (7), 387-394.
91. Edwards, G.F.; Steel, A.E.; Scott, J.K.; Jordan, J.W., Scarboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction. Chest, 1976, 70, (4), 506-513.
92. Miskoviti, G.; Szule, P.; Mescaros, K., Double blind study of carbocysteine against placebo in chronic bronchitis; Mucoregulation in respiratory tract disorders. Proc R Soc Med, 1982, 5, 1-3.
93. Puchelle, E.; Girard, F.; Zahm, J.M., [Rheology of bronchial secretions and mucociliary transport (author's transl)]. Bull Eur Physiopathol Respir, 1976, 12, (6), 771-779.
94. Allegra, L.; Cordaro, C.I.; Grassi, C., Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: A multicenter, double-blind, placebocontrolled trial. Respiration, 1996, 63, (3), 174-180.
95. Grillage, M.; Barnard-Jones, K., Long-term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. Br J Clin Pract, 1985, 39, (10), 395-398.
96. Yasuda, H.; Yamaya, M.; Sasaki, T.; Inoue, D.; Nakayama, K.; Tomita, N.; Yoshida, M.; Sasaki, H., Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc, 2006, 54, (2), 378-380.
97. Yasuda, H.; Yamaya, M.; Sasaki, T.; Inoue, D.; Nakayama, K.; Yamada, M.; Asada, M.; Yoshida, M.; Suzuki, T.; Nishimura, H.; Sasaki, H., Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur Respir J, 2006, 28, (1), 51-58.
98. Rhee, C.K.; Kang, C.M.; You, M.B.; Yoon, H.K.; Kim, Y.K.; Kim, K.H.; Moon, H.S.; Park, S.H.; Song, J.S., Effect of fudosteine on mucin production. Eur Respir J, 2008, 32, (5), 1195-1202.
99. Komatsu, H.; Yamaguchi, S.; Komorita, N.; Goto, K.; Takagi, S.; Ochi, H.; Okumoto, T., Inhibition of endotoxin-and antigeninduced airway inflammation by fudosteine, a mucoactive agent. Pulm Pharmacol Ther, 2005, 18, (2), 121-127.
100. Nagaoka, S.; Takishima, T.; Nagano, H.; Kawakami, Y.; Kitamua, S.; Kawakami, M.; Ogura, T.; Sasaki, T.; Ogawa, N., Phase III Clinical Study of SS320A. Double-blind Trial in Comparison with Placebo. Journal of Clinical Therapeutics & Medicines, 2002, 18, (1), 109-140.
101. Takahashi, K.; Iwase, N.; Ishikawa, M.; Mizuno, H.; Koda, T.; Kai, H.; Miyata, T., [Effects of fudosteine, a new cysteine derivative, on airway secretion in rabbits and rats]. Nihon Yakurigaku Zasshi, 2000, 116, (6), 371-378.
102. Osoata, G.O.; Hanazawa, T.; Brindicci, C.; Ito, M.; Barnes, P.J.; Kharitonov, S.; Ito, K., Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest, 2009, 135, (6), 1513-1520.
103. Moncaster, J.A.; Walsh, D.T.; Gentleman, S.M.; Jen, L.S.; Aruoma, O.I., Ergothioneine treatment protects neurons against Nmethyl-D-aspartate excitotoxicity in an in vivo rat retinal model. Neurosci Lett, 2002, 328, (1), 55-59.
104. Aruoma, O.I.; Whiteman, M.; England, T.G.; Halliwell, B., Antioxidant action of ergothioneine: Assessment of its ability to scavenge peroxynitrite. Biochem Biophys Res Commun, 1997, 231, (2), 389-391.
105. Aruoma, O.I.; Spencer, J.P.; Mahmood, N., Protection against oxidative damage and cell death by the natural antioxidant ergothioneine. Food Chem Toxicol, 1999, 37, (11), 1043-1053.
106. Misiti, F.; Castagnola, M.; Zuppi, C.; Giardina, B.; Messana, I., Role of ergothioneine on S-nitrosoglutathione catabolism. Biochem J, 2001, 356, (Pt 3), 799-804.
107. Rahman, I.; Gilmour, P.S.; Jimenez, L.A.; Biswas, S.K.; Antonicelli, F.; Aruoma, O.I., Ergothioneine inhibits oxidative stress-and TNF-alpha-induced NF-kappa B activation and interleukin-8 release in alveolar epithelial cells. Biochem Biophys Res Commun, 2003, 302, (4), 860-864.
108. Kensler, T.W.; Wakabayashi, N.; Biswal, S., Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol, 2007, 47, 89-116.
109. Rangasamy, T.; Guo, J.; Mitzner, W.A.; Roman, J.; Singh, A.; Fryer, A.D.; Yamamoto, M.; Kensler, T.W.; Tuder, R.M.; Georas, S.N.; Biswal, S., Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med, 2005, 202, (1), 47-59.
110. Sussan, T.E.; Rangasamy, T.; Blake, D.J.; Malhotra, D.; El-Haddad, H.; Bedja, D.; Yates, M.S.; Kombairaju, P.; Yamamoto, M.; Liby, K.T.; Sporn, M.B.; Gabrielson, K.L.; Champion, H.C.; Tuder, R.M.; Kensler, T.W.; Biswal, S., Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci U S A, 2009, 106, (1), 250-255.
111. Surh, Y.J.; Kundu, J.K.; Na, H.K., Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med, 2008, 74, (13), 1526-1539.
112. Giudice, A.; Arra, C.; Turco, M.C., Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. Methods Mol Biol, 2010, 647, 37-74.
113. Wan, J.; Diaz-Sanchez, D., Antioxidant enzyme induction: A new protective approach against the adverse effects of diesel exhaust particles. Inhal Toxicol, 2007, 19, 177-182.
114. Singh, A.; Rangasamy, T.; Thimmulappa, R.K.; Lee, H.; Osburn, W.O.; Brigelius-Flohe, R.; Kensler, T.W.; Yamamoto, M.; Biswal, S., Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2. Am. J. Respir. Cell Mol. Biol., 2006, 35, (6), 639-650.
115. Rangasamy, T.; Cho, C.Y.; Thimmulappa, R.K.; Zhen, L.; Srisuma, S.S.; Kensler, T.W.; Yamamoto, M.; Petrache, I.; Tuder, R.M.; Biswal, S., Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest, 2004, 114, (9), 1248-1259.
116. Iizuka, T.; Ishii, Y.; Itoh, K.; Kiwamoto, T.; Kimura, T.; Matsuno, Y.; Morishima, Y.; Hegab, A.E.; Homma, S.; Nomura, A.; Sakamoto, T.; Shimura, M.; Yoshida, A.; Yamamoto, M.; Sekizawa, K., Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells, 2005, 10, (12), 1113-1125.
117. Goven, D.; Boutten, A.; Lecon-Malas, V.; Marchal-Somme, J.; Amara, N.; Crestani, B.; Fournier, M.; Leseche, G.; Soler, P.; Boczkowski, J.; Bonay, M., Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax, 2008, 63, (10), 916-924.
118. Malhotra, D.; Thimmulappa, R.; Navas-Acien, A.; Sandford, A.; Elliott, M.; Singh, A.; Chen, L.; Zhuang, X.; Hogg, J.; Pare, P.; Tuder, R.M.; Biswal, S., Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am. J. Respir. Crit. Care Med., 2008, 178, (6), 592-604.
119. Suzuki, M.; Betsuyaku, T.; Ito, Y.; Nagai, K.; Nasuhara, Y.; Kaga, K.; Kondo, S.; Nishimura, M., Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol., 2008, 39, (6), 673-682.
120. Thimmulappa, R.K.; Scollick, C.; Traore, K.; Yates, M.; Trush, M.A.; Liby, K.T.; Sporn, M.B.; Yamamoto, M.; Kensler, T.W.; Biswal, S., Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem Biophys Res Commun, 2006, 351, (4), 883-889.
121. Adenuga, D.; Yao, H.; March, T.H.; Seagrave, J.; Rahman, I., Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am. J. Respir. Cell Mol. Biol., 2009, 40, (4), 464-473.
122. Ito, K.; Ito, M.; Elliott, W.M.; Cosio, B.; Caramori, G.; Kon, O.M.; Barczyk, A.; Hayashi, S.; Adcock, I.M.; Hogg, J.C.; Barnes, P.J., Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med, 2005, 352, (19), 1967-1976.
123. Mercado, N.; Thimmulappa, R.; Thomas, C.M.; Fenwick, P.S.; Chana, K.K.; Donnelly, L.E.; Biswal, S.; Ito, K.; Barnes, P.J., Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun, 2011, 406, (2), 292-298.
124. Adenuga, D.; Caito, S.; Yao, H.; Sundar, I.K.; Hwang, J.W.; Chung, S.; Rahman, I., Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction. Biochem Biophys Res Commun, 2010, 403, (3-4), 452-456.
125. Meja, K.K.; Rajendrasozhan, S.; Adenuga, D.; Biswas, S.K.; Sundar, I.K.; Spooner, G.; Marwick, J.A.; Chakravarty, P.; Fletcher, D.; Whittaker, P.; Megson, I.L.; Kirkham, P.A.; Rahman, I., Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am. J. Respir. Cell Mol. Biol., 2008, 39, (3), 312-323.
126. Osoata, G.O.; Yamamura, S.; Ito, M.; Vuppusetty, C.; Adcock, I.M.; Barnes, P.J.; Ito, K., Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Biophys Res Commun, 2009, 384, (3), 366-371.
127. Nott, A.; Watson, P.M.; Robinson, J.D.; Crepaldi, L.; Riccio, A., SNitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature, 2008, 455, (7211), 411-415.
128. Malhotra, D.; Thimmulappa, R.K.; Mercado, N.; Ito, K.; Kombairaju, P.; Kumar, S.; Ma, J.; Feller-Kopman, D.; Wise, R.; Barnes, P.; Biswal, S., Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J Clin Invest, 2011.
129. Doyle, K.; Fitzpatrick, F.A., Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J Biol Chem, 2010, 285, (23), 17417-17424.
130. Ebert, B.; Kisiela, M.; Malatkova, P.; El-Hawari, Y.; Maser, E., Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells. Biochemistry, 2010, 49, (39), 8499-8511.
131. Kode, A.; Rajendrasozhan, S.; Caito, S.; Yang, S.R.; Megson, I.L.; Rahman, I., Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2008, 294, (3), L478-488.
132. Milara, J.; Navarro, A.; Almudever, P.; Lluch, J.; Morcillo, E.J.; Cortijo, J., Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy, 2011, 41, (4), 535-546.
133. Thimmulappa, R.K.; Mai, K.H.; Srisuma, S.; Kensler, T.W.; Yamamoto, M.; Biswal, S., Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res, 2002, 62, (18), 5196-5203.
134. Kwak, M.K.; Wakabayashi, N.; Itoh, K.; Motohashi, H.; Yamamoto, M.; Kensler, T.W., Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem, 2003, 278, (10), 8135-8145.
135. Balogun, E.; Hoque, M.; Gong, P.; Killeen, E.; Green, C.J.; Foresti, R.; Alam, J.; Motterlini, R., Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidantresponsive element. Biochem J, 2003, 371, (Pt 3), 887-895.
136. Go, M.L.; Wu, X.; Liu, X.L., Chalcones: An update on cytotoxic and chemoprotective properties. Curr. Med. Chem., 2005, 12, (4), 481-499.
137. Wei, B.L.; Teng, C.H.; Wang, J.P.; Won, S.J.; Lin, C.N., Synthetic 2',5'-dimethoxychalcones as G(2)/M arrest-mediated apoptosisinducing agents and inhibitors of nitric oxide production in rat macrophages. Eur J Med Chem, 2007, 42, (5), 660-668.
138. Lee, J.H.; Jung, H.S.; Giang, P.M.; Jin, X.; Lee, S.; Son, P.T.; Lee, D.; Hong, Y.S.; Lee, K.; Lee, J.J., Blockade of nuclear factorkappaB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J Pharmacol Exp Ther, 2006, 316, (1), 271-278.
139. Liu, Y.C.; Hsieh, C.W.; Wu, C.C.; Wung, B.S., Chalcone inhibits the activation of NF-kappaB and STAT3 in endothelial cells via endogenous electrophile. Life Sci, 2007, 80, (15), 1420-1430.
140. Foresti, R.; Hoque, M.; Monti, D.; Green, C.J.; Motterlini, R., Differential activation of heme oxygenase-1 by chalcones and rosolic acid in endothelial cells. J Pharmacol Exp Ther, 2005, 312, (2), 686-693.
141. Yang, Y.C.; Lii, C.K.; Lin, A.H.; Yeh, Y.W.; Yao, H.T.; Li, C.C.; Liu, K.L.; Chen, H.W., Induction of glutathione synthesis and heme oxygenase 1 by the flavonoids butein and phloretin is mediated through the ERK/Nrf2 pathway and protects against oxidative stress. Free Radic Biol Med, 2011, 51, (11), 2073-2081.
142. Kumar, V.; Kumar, S.; Hassan, M.; Wu, H.; Thimmulappa, R.K.; Kumar, A.; Sharma, S.K.; Parmar, V.S.; Biswal, S.; Malhotra, S.V., Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. J Med Chem, 2011, 54, (12), 4147-4159.
143. Tajima, S.; Bando, M.; Ishii, Y.; Hosono, T.; Yamasawa, H.; Ohno, S.; Takada, T.; Suzuki, E.; Gejyo, F.; Sugiyama, Y., Effects of edaravone, a free-radical scavenger, on bleomycin-induced lung injury in mice. Eur Respir J, 2008, 32, (5), 1337-1343.
144. Kikuchi, K.; Uchikado, H.; Miyagi, N.; Morimoto, Y.; Ito, T.; Tancharoen, S.; Miura, N.; Miyata, K.; Sakamoto, R.; Kikuchi, C.; Iida, N.; Shiomi, N.; Kuramoto, T.; Kawahara, K., Beyond neurological disease: New targets for edaravone (Review). Int J Mol Med, 2011, 28, (6), 899-906.
145. Aldini, G.; Vistoli, G.; Regazzoni, L.; Benfatto, M.C.; Bettinelli, I.; Carini, M., Edaravone inhibits protein carbonylation by a direct carbonyl-scavenging mechanism: Focus on reactivity, selectivity, and reaction mechanisms. Antioxid Redox Signal, 2010, 12, (3), 381-392.
146. Aldini, G.; Dalle-Donne, I.; Facino, R.M.; Milzani, A.; Carini, M., Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med Res Rev, 2007, 27, (6), 817-868.
147. Kawai, H.; Nakai, H.; Suga, M.; Yuki, S.; Watanabe, T.; Saito, K.I., Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther, 1997, 281, (2), 921-927.
148. Watanabe, T.; Yuki, S.; Egawa, M.; Nishi, H., Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther, 1994, 268, (3), 1597-1604.
149. Wu, T.W.; Zeng, L.H.; Wu, J.; Fung, K.P., MCI-186: Further histochemical and biochemical evidence of neuroprotection. Life Sci, 2000, 67, (19), 2387-2392.
150. Ito, K.; Ozasa, H.; Horikawa, S., Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. Free Radic Biol Med, 2005, 38, (3), 369-374.
151. Asai, T.; Ohno, Y.; Minatoguchi, S.; Funaguchi, N.; Yuhgetsu, H.; Sawada, M.; Takemura, G.; Komada, A.; Fujiwara, T.; Fujiwara, H., The specific free radical scavenger edaravone suppresses bleomycin-induced acute pulmonary injury in rabbits. Clin Exp Pharmacol Physiol, 2007, 34, (1-2), 22-26.
152. Zhi, Q.; Sun, H.; Qian, X.; Yang, L., Edaravone, a novel antidote against lung injury and pulmonary fibrosis induced by paraquat? Int Immunopharmacol, 2011, 11, (1), 96-102.
153. Yoshizaki, A.; Yanaba, K.; Ogawa, A.; Iwata, Y.; Ogawa, F.; Takenaka, M.; Shimizu, K.; Asano, Y.; Kadono, T.; Sato, S., The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum, 2011, 63, (10), 3086-3097.
154. Fujita, M.; Mizuta, Y.; Ikegame, S.; Ouchi, H.; Ye, Q.; Harada, E.; Inoshima, I.; Yoshimi, M.; Watanabe, K.; Nakanishi, Y., Biphasic effects of free radical scavengers against bleomycin-induced pulmonary fibrosis. Pulm Pharmacol Ther, 2008, 21, (5), 805-811.
155. Isahaya, K.; Yamada, K.; Yamatoku, M.; Sakurai, K.; Takaishi, S.; Kato, B.; Hirayama, T.; Hasegawa, Y., Effects of Edaravone, a Free Radical Scavenger, on Serum Levels of Inflammatory Biomarkers in Acute Brain Infarction. J Stroke Cerebrovasc Dis, 2011.
156. Yang, T.; Mao, Y.F.; Liu, S.Q.; Hou, J.; Cai, Z.Y.; Hu, J.Y.; Ni, X.; Deng, X.M.; Zhu, X.Y., Protective effects of the free radical scavenger edaravone on acute pancreatitis-associated lung injury. Eur J Pharmacol, 2010, 630, (1-3), 152-157.
157. Kitson, T.M., The activation of aldehyde dehydrogenase by diethylstilboestrol and 2,2'-dithiodipyridine. Biochem J, 1982, 207, (1), 81-89.
158. Chen, C.H.; Budas, G.R.; Churchill, E.N.; Disatnik, M.H.; Hurley, T.D.; Mochly-Rosen, D., Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science, 2008, 321, (5895), 1493-1495.
159. Braughler, J.M.; Pregenzer, J.F.; Chase, R.L.; Duncan, L.A.; Jacobsen, E.J.; McCall, J.M., Novel 21-amino steroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem, 1987, 262, (22), 10438-10440.
160. Miniati, M.; Cocci, F.; Monti, S.; Filippi, E.; Sarnelli, R.; Ferdeghini, M.; Gattai, V.; Pistolesi, M., Lazaroid U-74389F attenuates phorbol ester-induced lung injury in rabbits. Eur Respir J, 1996, 9, (4), 758-764.
161. Shenkar, R.; Abraham, E., Effects of treatment with the 21-aminosteroid, U7438F, on pulmonary cytokine expression following hemorrhage and resuscitation. Crit Care Med, 1995, 23, (1), 132-139.
162. Wang, S.; Lantz, R.C.; Rider, E.D.; Chen, G.J.; Breceda, V.; Hays, A.M.; Robledo, R.F.; Tollinger, B.J.; Dinesh, S.V.; Witten, M.L., A free radical scavenger (Lazaroid U75412E) attenuates tumor necrosis factor-alpha generation in a rabbit model of smokeinduced lung injury. Respiration, 1997, 64, (5), 358-363.
163. Wang, S.; Lantz, R.C.; Vermeulen, M.W.; Chen, G.J.; Breceda, V.; Robledo, R.F.; Hays, A.M.; Young, S.; Witten, M.L., Functional alterations of alveolar macrophages subjected to smoke exposure and antioxidant lazaroids. Toxicol Ind Health, 1999, 15, (5), 464-469.
164. Tanigaki, T.; Suzuki, Y.; Heimer, D.; Sussman, H.H.; Ross, W.G.; Raffin, T.A., Attenuation of acute lung injury and oxygen radical production by the 21-aminosteroid, U-78518F. J Appl Physiol, 1993, 74, (5), 2155-2160.
165. van Klaveren, R.J.; Roelant, C.; Boogaerts, M.; Pype, J.L.; Demedts, M.; Nemery, B., Protective effects of the lazaroid U-74389G against hyperoxia in rat type II pneumocytes. Pulm Pharmacol Ther, 1998, 11, (1), 23-30.
166. Fujimoto, K.; Kubo, K.; Okada, K.; Kobayashi, T.; Sekiguchi, M.; Sakai, A., Effect of the 21-aminosteroid U-74006F on antigeninduced bronchoconstriction and bronchoalveolar eosinophilia in allergic sheep. Eur Respir J, 1996, 9, (10), 2044-2049.
167. Kubo, K.; Amari, T.; Kaneki, T.; Hanaoka, M.; Hayano, T.; Miyahara, T.; Koyama, S.; Koizumi, T.; Fujimoto, K.; Kobayashi, T., A 21-aminosteroid, U-74006F, attenuates endotoxin-induced lung injury in awake sheep. Respirology, 1999, 4, (2), 167-172.
168. Nakayama, M.; Hasegawa, N.; Oka, Y.; Lutzke, B.; McCall, J.M.; Raffin, T.A., Effects of the lazaroid, tirilazad mesylate, on sepsisinduced acute lung injury in minipigs. Crit Care Med, 1998, 26, (3), 538-547.
169. Griffin, R.L.; Krzesicki, R.F.; Fidler, S.F.; Rosenbloom, C.L.; Auchampach, J.A.; Manning, A.M.; Haas, J.V.; Cammarata, S.K.; Chin, J.E.; Richards, I.M., Attenuation of oxidant-induced lung injury by 21-aminosteroids (lazaroids): Correlation with the mRNA expression for E-selectin, P-selectin, ICAM-1, and VCAM-1. Environ Health Perspect, 1994, 102 Suppl 10, 193-200.
170. Hoon, S.; Gebbia, M.; Costanzo, M.; Davis, R.; Giaever, G.; Nislow, C., A Global Perspective of the Genetic Basis for Carbonyl Stress Resistance. G3: Genes, Genomes, Genetics 2011, 1, (3), 219-231.
171. Siems, W.; Grune, T., Intracellular metabolism of 4-hydroxynonenal. Mol Aspects Med, 2003, 24, (4-5), 167-175.
172. Thornalley, P.J., Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans, 2003, 31, (Pt 6), 1343-1348.
173. Vander Jagt, D.L.; Hassebrook, R.K.; Hunsaker, L.A.; Brown, W.M.; Royer, R.E., Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: Roles for glutathione in both enzymes and implications for diabetic complications. Chem Biol Interact, 2001, 130-132, (1-3), 549-562.
174. Shringarpure, R.; Grune, T.; Sitte, N.; Davies, K.J., 4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: Possible importance in Alzheimer's disease. Cell Mol Life Sci, 2000, 57, (12), 1802-1809.
175. Okada, K.; Wangpoengtrakul, C.; Osawa, T.; Toyokuni, S.; Tanaka, K.; Uchida, K., 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem, 1999, 274, (34), 23787-23793.
176. Miyata, T.; Ueda, Y.; Asahi, K.; Izuhara, Y.; Inagi, R.; Saito, A.; Van Ypersele De Strihou, C.; Kurokawa, K., Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol, 2000, 11, (9), 1719-1725.
177. Kaminskas, L.M.; Pyke, S.M.; Burcham, P.C., Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice. J Pharmacol Exp Ther, 2004, 310, (3), 1003-1010.
178. Vindis, C.; Escargueil-Blanc, I.; Elbaz, M.; Marcheix, B.; Grazide, M.H.; Uchida, K.; Salvayre, R.; Negre-Salvayre, A., Desensitization of platelet-derived growth factor receptor-beta by oxidized lipids in vascular cells and atherosclerotic lesions: Prevention by aldehyde scavengers. Circ Res, 2006, 98, (6), 785-792.
179. Altuntas, Y.; Guven, M.; Ince, E.; Acbay, O.; Caner, M.; Kanigur-Sultuybek, G., The in vitro effects of captopril on the levels of lipid peroxidation and glutathione of erythrocytes in type II diabetes. J Basic Clin Physiol Pharmacol, 1995, 6, (3-4), 281-288.
180. Hipkiss, A.R.; Preston, J.E.; Himswoth, D.T.; Worthington, V.C.; Abbot, N.J., Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci Lett, 1997, 238, (3), 135-138.
181. Hipkiss, A.R.; Brownson, C.; Carrier, M.J., Carnosine, the antiageing, anti-oxidant dipeptide, may react with protein carbonyl groups. Mech Ageing Dev, 2001, 122, (13), 1431-1445.
182. Tuder, R.M.; Zhen, L.; Cho, C.Y.; Taraseviciene-Stewart, L.; Kasahara, Y.; Salvemini, D.; Voelkel, N.F.; Flores, S.C., Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am. J. Respir. Cell Mol. Biol., 2003, 29, (1), 88-97.
183. Muscoli, C.; Sacco, I.; Alecce, W.; Palma, E.; Nistico, R.; Costa, N.; Clementi, F.; Rotiroti, D.; Romeo, F.; Salvemini, D.; Mehta, J.L.; Mollace, V., The protective effect of superoxide dismutase mimetic M40401 on balloon injury-related neointima formation: Role of the lectin-like oxidized low-density lipoprotein receptor-1. J Pharmacol Exp Ther, 2004, 311, (1), 44-50.
184. Chang, L.Y.; Crapo, J.D., Inhibition of airway inflammation and hyperreactivity by an antioxidant mimetic. Free Radic Biol Med, 2002, 33, (3), 379-386.
185. Smith, K.R.; Uyeminami, D.L.; Kodavanti, U.P.; Crapo, J.D.; Chang, L.Y.; Pinkerton, K.E., Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med, 2002, 33, (8), 1106-1114.
186. Sharpe, M.A.; Ollosson, R.; Stewart, V.C.; Clark, J.B., Oxidation of nitric oxide by oxomanganese-salen complexes: A new mechanism for cellular protection by superoxide dismutase/catalase mimetics. Biochem J, 2002, 366, (Pt 1), 97-107.
187. Nishikawa, M.; Kakemizu, N.; Ito, T.; Kudo, M.; Kaneko, T.; Suzuki, M.; Udaka, N.; Ikeda, H.; Okubo, T., Superoxide mediates cigarette smoke-induced infiltration of neutrophils into the airways through nuclear factor-kappaB activation and IL-8 mRNA expression in guinea pigs in vivo. Am. J. Respir. Cell Mol. Biol., 1999, 20, (2), 189-198.
188. Day, B.J.; Shawen, S.; Liochev, S.I.; Crapo, J.D., A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. J Pharmacol Exp Ther, 1995, 275, (3), 1227-1232.
189. Day, B.J.; Fridovich, I.; Crapo, J.D., Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide-mediated injury. Arch Biochem Biophys, 1997, 347, (2), 256-262.
190. Ferrer-Sueta, G.; Vitturi, D.; Batinic-Haberle, I.; Fridovich, I.; Goldstein, S.; Czapski, G.; Radi, R., Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J Biol Chem, 2003, 278, (30), 27432-27438.
191. Tse, H.M.; Milton, M.J.; Piganelli, J.D., Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: Implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic Biol Med, 2004, 36, (2), 233-247.
192. Vujaskovic, Z.; Batinic-Haberle, I.; Rabbani, Z.N.; Feng, Q.F.; Kang, S.K.; Spasojevic, I.; Samulski, T.V.; Fridovich, I.; Dewhirst, M.W.; Anscher, M.S., A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med, 2002, 33, (6), 857-863.
193. Piganelli, J.D.; Flores, S.C.; Cruz, C.; Koepp, J.; Batinic-Haberle, I.; Crapo, J.; Day, B.; Kachadourian, R.; Young, R.; Bradley, B.; Haskins, K., A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes, 2002, 51, (2), 347-355.
194. Zhang, H.J.; Doctrow, S.R.; Xu, L.; Oberley, L.W.; Beecher, B.; Morrison, J.; Oberley, T.D.; Kregel, K.C., Redox modulation of the liver with chronic antioxidant enzyme mimetic treatment prevents age-related oxidative damage associated with environmental stress. FASEB J, 2004, 18, (13), 1547-1549.
195. Zhang, H.J.; Doctrow, S.R.; Oberley, L.W.; Kregel, K.C., Chronic antioxidant enzyme mimetic treatment differentially modulates hyperthermia-induced liver HSP70 expression with aging. J Appl Physiol, 2006, 100, (4), 1385-1391.
196. Podowski, M.; Calvi, C.L.; Cheadle, C.; Tuder, R.M.; Biswals, S.; Neptune, E.R., Complex integration of matrix, oxidative stress, and apoptosis in genetic emphysema. Am J Pathol, 2009, 175, (1), 84-96.
197. Foronjy, R.F.; Mirochnitchenko, O.; Propokenko, O.; Lemaitre, V.; Jia, Y.; Inouye, M.; Okada, Y.; D'Armiento, J.M., Superoxide dismutase expression attenuates cigarette smoke-or elastasegenerated emphysema in mice. Am. J. Respir. Crit. Care Med., 2006, 173, (6), 623-631.
198. Clarke, M.B.; Wright, R.; Irwin, D.; Bose, S.; Van Rheen, Z.; Birari, R.; Stenmark, K.R.; McCord, J.M.; Nozik-Grayck, E., Sustained lung activity of a novel chimeric protein, SOD2/3, after intratracheal administration. Free Radic Biol Med, 2010, 49, (12), 2032-2039.
199. Preissler, G.; Loehe, F.; Huff, I.V.; Ebersberger, U.; Shuvaev, V.V.; Bittmann, I.; Hermanns, I.; Kirkpatrick, J.C.; Fischer, K.; Eichhorn, M.E.; Winter, H.; Jauch, K.W.; Albelda, S.M.; Muzykantov, V.R.; Wiewrodt, R., Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death. Transplantation, 2011, 92, (4), 380-387.
200. Kinnula, V.L.; Crapo, J.D., Superoxide dismutases in the lung and human lung diseases. Am. J. Respir. Crit. Care Med., 2003, 167, (12), 1600-1619.
201. Gongora, M.C.; Lob, H.E.; Landmesser, U.; Guzik, T.J.; Martin, W.D.; Ozumi, K.; Wall, S.M.; Wilson, D.S.; Murthy, N.; Gravanis, M.; Fukai, T.; Harrison, D.G., Loss of extracellular superoxide dismutase leads to acute lung damage in the presence of ambient air: A potential mechanism underlying adult respiratory distress syndrome. Am J Pathol, 2008, 173, (4), 915-926.
202. Folz, R.J.; Abushamaa, A.M.; Suliman, H.B., Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. J Clin Invest, 1999, 103, (7), 1055-1066.
203. Yao, H.; Arunachalam, G.; Hwang, J.W.; Chung, S.; Sundar, I.K.; Kinnula, V.L.; Crapo, J.D.; Rahman, I., Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM. Proc Natl Acad Sci U S A, 2010, 107, (35), 15571-15576.
204. Tollefson, A.K.; Oberley-Deegan, R.E.; Butterfield, K.T.; Nicks, M.E.; Weaver, M.R.; Remigio, L.K.; Decsesznak, J.; Chu, H.W.; Bratton, D.L.; Riches, D.W.; Bowler, R.P., Endogenous enzymes (NOX and ECSOD) regulate smoke-induced oxidative stress. Free Radic Biol Med, 2010, 49, (12), 1937-1946.
205. Regan, E.A.; Mazur, W.; Meoni, E.; Toljamo, T.; Millar, J.; Vuopala, K.; Bowler, R.P.; Rahman, I.; Nicks, M.E.; Crapo, J.D.; Kinnula, V.L., Smoking and COPD increase sputum levels of extracellular superoxide dismutase. Free Radic Biol Med, 2011, 51, (3), 726-732.
206. Sorheim, I.C.; DeMeo, D.L.; Washko, G.; Litonjua, A.; Sparrow, D.; Bowler, R.; Bakke, P.; Pillai, S.G.; Coxson, H.O.; Lomas, D.A.; Silverman, E.K.; Hersh, C.P., Polymorphisms in the superoxide dismutase-3 gene are associated with emphysema in COPD. COPD, 2010, 7, (4), 262-268.
207. Dahl, M.; Bowler, R.P.; Juul, K.; Crapo, J.D.; Levy, S.; Nordestgaard, B.G., Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations. Am. J. Respir. Crit. Care Med., 2008, 178, (9), 906-912.
208. Jozsef, L.; Filep, J.G., Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. Free Radic Biol Med, 2003, 35, (9), 1018-1027.
209. Haddad el, B.; McCluskie, K.; Birrell, M.A.; Dabrowski, D.; Pecoraro, M.; Underwood, S.; Chen, B.; De Sanctis, G.T.; Webber, S.E.; Foster, M.L.; Belvisi, M.G., Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. J Immunol, 2002, 169, (2), 974-982.
210. Zhang, M.; Nomura, A.; Uchida, Y.; Iijima, H.; Sakamoto, T.; Iishii, Y.; Morishima, Y.; Mochizuki, M.; Masuyama, K.; Hirano, K.; Sekizawa, K., Ebselen suppresses late airway responses and airway inflammation in guinea pigs. Free Radic Biol Med, 2002, 32, (5), 454-464.
211. Moutet, M.; d'Alessio, P.; Malette, P.; Devaux, V.; Chaudiere, J., Glutathione peroxidase mimics prevent TNFalpha-and neutrophilinduced endothelial alterations. Free Radic Biol Med, 1998, 25, (3), 270-281.
212. Stefanutti, G.; Pierro, A.; Smith, V.V.; Klein, N.J.; Eaton, S., Peroxynitrite decomposition catalyst FeTMPyP provides partial protection against intestinal ischemia and reperfusion injury in infant rats. Pediatr Res, 2007, 62, (1), 43-48.
213. Pacher, P.; Liaudet, L.; Bai, P.; Mabley, J.G.; Kaminski, P.M.; Virag, L.; Deb, A.; Szabo, E.; Ungvari, Z.; Wolin, M.S.; Groves, J.T.; Szabo, C., Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation, 2003, 107, (6), 896-904.
214. Cuzzocrea, S.; Thiemermann, C.; Salvemini, D., Potential therapeutic effect of antioxidant therapy in shock and inflammation. Curr. Med. Chem., 2004, 11, (9), 1147-1162.
215. Chabrier, P.E.; Auguet, M.; Spinnewyn, B.; Auvin, S.; Cornet, S.; Demerle-Pallardy, C.; Guilmard-Favre, C.; Marin, J.G.; Pignol, B.; Gillard-Roubert, V.; Roussillot-Charnet, C.; Schulz, J.; Viossat, I.; Bigg, D.; Moncada, S., BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: A promising neuroprotective strategy. Proc Natl Acad Sci U S A, 1999, 96, (19), 10824-10829.
216. Shi, H.; Timmins, G.; Monske, M.; Burdick, A.; Kalyanaraman, B.; Liu, Y.; Clement, J.L.; Burchiel, S.; Liu, K.J., Evaluation of spin trapping agents and trapping conditions for detection of cellgenerated reactive oxygen species. Arch Biochem Biophys, 2005, 437, (1), 59-68.
217. Becker, D.A., Diagnostic and therapeutic applications of azulenyl nitrone spin traps. Cell Mol Life Sci, 1999, 56, (7-8), 626-633.
218. Bottle, S.E.; Micallef, A.S., Synthesis and EPR spin trapping properties of a new isoindole-based nitrone: 1,1,3-trimethylisoindole N-oxide (TMINO). Org Biomol Chem, 2003, 1, (14), 2581-2584.
219. Becker, D.A.; Ley, J.J.; Echegoyen, L.; Alvarado, R., Stilbazulenyl nitrone (STAZN): A nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants. J Am Chem Soc, 2002, 124, (17), 4678-4684.
220. Valenca, S.S.; Rueff-Barroso, C.R.; Pimenta, W.A.; Melo, A.C.; Nesi, R.T.; Silva, M.A.; Porto, L.C., L-NAME and L-arginine differentially ameliorate cigarette smoke-induced emphysema in mice. Pulm Pharmacol Ther, 2011, 24, (5), 587-594.
221. Seimetz, M.; Parajuli, N.; Pichl, A.; Veit, F.; Kwapiszewska, G.; Weisel, F.C.; Milger, K.; Egemnazarov, B.; Turowska, A.; Fuchs, B.; Nikam, S.; Roth, M.; Sydykov, A.; Medebach, T.; Klepetko, W.; Jaksch, P.; Dumitrascu, R.; Garn, H.; Voswinckel, R.; Kostin, S.; Seeger, W.; Schermuly, R.T.; Grimminger, F.; Ghofrani, H.A.; Weissmann, N., Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. Cell, 2011, 147, (2), 293-305.
222. Brindicci, C.; Kharitonov, S.A.; Ito, M.; Elliott, M.W.; Hogg, J.C.; Barnes, P.J.; Ito, K., Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2010, 181, (1), 21-30.
223. Tiden, A.K.; Sjogren, T.; Svensson, M.; Bernlind, A.; Senthilmohan, R.; Auchere, F.; Norman, H.; Markgren, P.O.; Gustavsson, S.; Schmidt, S.; Lundquist, S.; Forbes, L.V.; Magon, N.J.; Paton, L.N.; Jameson, G.N.; Eriksson, H.; Kettle, A.J., 2-Thioxanthines Are Mechanism-based Inactivators of Myeloperoxidase That Block Oxidative Stress during Inflammation. J Biol Chem, 2011, 286, (43), 37578-37589.
224. Churg, A.; Marshall, C.V.; Sin, D.D.; Bolton, S.; Zhou, S.; Thain, K.; Cadogan, E.B.; Maltby, J.; Soars, M.G.; Mallinder, P.R.; Wright, J.L., Late Intervention with a Myeloperoxidase Inhibitor Stops Progression of Experimental COPD. Am. J. Respir. Crit. Care Med., 2011.
225. Geraets, L.; Haegens, A.; Weseler, A.R.; Brauers, K.; Vernooy, J.H.; Wouters, E.F.; Bast, A.; Hageman, G.J., Inhibition of acute pulmonary and systemic inflammation by 1,7-dimethylxanthine. Eur J Pharmacol, 2010, 629, (1-3), 132-139.
226. Fiorucci, S., Hydrogen sulfide: From physiology to pharmacology. Inflamm Allergy Drug Targets, 2011, 10, (2), 77-84.
227. Perry, M.M.; Hui, C.K.; Whiteman, M.; Wood, M.E.; Adcock, I.; Kirkham, P.; Michaeloudes, C.; Chung, K.F., Hydrogen sulfide inhibits proliferation and release of IL-8 from human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol., 2011, 45, (4), 746-752.
228. Han, W.; Dong, Z.; Dimitropoulou, C.; Su, Y., Hydrogen sulfide ameliorates tobacco smoke-induced oxidative stress and emphysema in mice. Antioxid Redox Signal, 2011, 15, (8), 2121-2134.
229. Chen, Y.H.; Wang, P.P.; Wang, X.M.; He, Y.J.; Yao, W.Z.; Qi, Y.F.; Tang, C.S., Involvement of endogenous hydrogen sulfide in cigarette smoke-induced changes in airway responsiveness and inflammation of rat lung. Cytokine, 2011, 53, (3), 334-341.
230. Chen, Y.H.; Yao, W.Z.; Geng, B.; Ding, Y.L.; Lu, M.; Zhao, M.W.; Tang, C.S., Endogenous hydrogen sulfide in patients with COPD. Chest, 2005, 128, (5), 3205-3211.
231. Li, Y.; Liu, W.; Xing, G.; Tian, C.; Zhu, Y.; He, F., Direct association of hepatopoietin with thioredoxin constitutes a redox signal transduction in activation of AP-1/NF-kappaB. Cell Signal, 2005, 17, (8), 985-996.
232. Saitoh, M.; Nishitoh, H.; Fujii, M.; Takeda, K.; Tobiume, K.; Sawada, Y.; Kawabata, M.; Miyazono, K.; Ichijo, H., Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J, 1998, 17, (9), 2596-2606.
233. Qin, J.; Clore, G.M.; Kennedy, W.M.; Huth, J.R.; Gronenborn, A.M., Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF kappa B. Structure, 1995, 3, (3), 289-297.
234. Filomeni, G.; Rotilio, G.; Ciriolo, M.R., Cell signalling and the glutathione redox system. Biochem Pharmacol, 2002, 64, (5-6), 1057-1064.
235. Souza, D.G.; Vieira, A.T.; Pinho, V.; Sousa, L.P.; Andrade, A.A.; Bonjardim, C.A.; McMillan, M.; Kahn, M.; Teixeira, M.M., NFkappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury. Br J Pharmacol, 2005, 145, (2), 246-254.
236. Nguyen, C.; Teo, J.L.; Matsuda, A.; Eguchi, M.; Chi, E.Y.; Henderson, W.R., Jr.; Kahn, M., Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc Natl Acad Sci U S A, 2003, 100, (3), 1169-1173.
237. Henderson, W.R., Jr.; Chi, E.Y.; Teo, J.L.; Nguyen, C.; Kahn, M., A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol, 2002, 169, (9), 5294-5299.
238. Sato, A.; Hoshino, Y.; Hara, T.; Muro, S.; Nakamura, H.; Mishima, M.; Yodoi, J., Thioredoxin-1 ameliorates cigarette smoke-induced lung inflammation and emphysema in mice. J Pharmacol Exp Ther, 2008, 325, (2), 380-388.
239. Bachnoff, N.; Trus, M.; Atlas, D., Alleviation of oxidative stress by potent and selective thioredoxin-mimetic peptides. Free Radic Biol Med, 2011, 50, (10), 1355-1367.
240. Hofmann, B.; Hecht, H.J.; Flohe, L., Peroxiredoxins. Biol Chem, 2002, 383, (3-4), 347-364.
241. Wood, Z.A.; Schroder, E.; Robin Harris, J.; Poole, L.B., Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci, 2003, 28, (1), 32-40.
242. Mo, Y.; Feinstein, S.I.; Manevich, Y.; Zhang, Q.; Lu, L.; Ho, Y.S.; Fisher, A.B., 1-Cys peroxiredoxin knock-out mice express mRNA but not protein for a highly related intronless gene. FEBS Lett, 2003, 555, (2), 192-198.
243. Kim, T.S.; Dodia, C.; Chen, X.; Hennigan, B.B.; Jain, M.; Feinstein, S.I.; Fisher, A.B., Cloning and expression of rat lung acidic Ca(2+)-independent PLA2 and its organ distribution. Am J Physiol, 1998, 274, (5 Pt 1), L750-761.
244. Lee, S.B.; Ho, J.N.; Yoon, S.H.; Kang, G.Y.; Hwang, S.G.; Um, H.D., Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt. Mol Cells, 2009, 28, (6), 583-588.
245. Neumann, C.A.; Krause, D.S.; Carman, C.V.; Das, S.; Dubey, D.P.; Abraham, J.L.; Bronson, R.T.; Fujiwara, Y.; Orkin, S.H.; Van Etten, R.A., Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature, 2003, 424, (6948), 561-565.
246. Sundar, I.K.; Chung, S.; Hwang, J.W.; Arunachalam, G.; Cook, S.; Yao, H.; Mazur, W.; Kinnula, V.L.; Fisher, A.B.; Rahman, I., Peroxiredoxin 6 differentially regulates acute and chronic cigarette smoke–mediated lung inflammatory response and injury. Exp. Lung Res., 2010, 36 (8), 451-462.
247. Peltoniemi, M.J.; Rytila, P.H.; Harju, T.H.; Soini, Y.M.; Salmenkivi, K.M.; Ruddock, L.W.; Kinnula, V.L., Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease. Respir. Res., 2006, 7, 133.
248. Kuipers, I.; Guala, A.S.; Aesif, S.W.; Konings, G.; Bouwman, F.G.; Mariman, E.C.; Wouters, E.F.; Janssen-Heininger, Y.M.; Reynaert, N.L., Cigarette Smoke Targets Glutaredoxin 1, Increasing S-glutathionylation and Epithelial Cell Death. Am. J. Respir. Cell Mol. Biol., 2011.
249. Nyunoya, T.; March, T.H.; Tesfaigzi, Y.; Seagrave, J., Antioxidant Diet Protects Against Emphysema, but Increases Mortality in Cigarette Smoke-Exposed Mice. COPD, 2011.
250. Lykkesfeldt, J.; Christen, S.; Wallock, L.M.; Chang, H.H.; Jacob, R.A.; Ames, B.N., Ascorbate is depleted by smoking and repleted by moderate supplementation: A study in male smokers and nonsmokers with matched dietary antioxidant intakes. Am. J. Clin. Nutr., 2000, 71 (2), 530-536.
251. Aghdassi, E.; Royall, D.; Allard, J.P., Oxidative stress in smokers supplemented with vitamin C. Int. J. Vitam. Nutr. Res., 1999, 69 (1), 45-51.
252. Habib, M.P.; Tank, L.J.; Lane, L.C.; Garewal, H.S., Effect of vitamin E on exhaled ethane in cigarette smokers. Chest, 1999, 115 (3), 684-690.
253. Steinberg, F.M.; Chait, A., Antioxidant vitamin supplementation and lipid peroxidation in smokers. Am. J. Clin. Nutr., 1998, 68 (2), 319-327.
254. Rautalahti, M.; Virtamo, J.; Haukka, J.; Heinonen, O.P.; Sundvall, J.; Albanes, D.; Huttunen, J.K., The effect of alpha-tocopherol and beta-carotene supplementation on COPD symptoms. Am. J. Respir. Crit. Care Med., 1997, 156 (5), 1447-1452.
255. Agler, A.H.; Kurth, T.; Gaziano, J.M.; Buring, J.E.; Cassano, P.A., Randomised vitamin E supplementation and risk of chronic lung disease in the Women's Health Study. Thorax, 2011, 66 (4), 320-325.
256. de Batlle, J.; Barreiro, E.; Romieu, I.; Mendez, M.; Gomez, F.P.; Balcells, E.; Ferrer, J.; Orozco-Levi, M.; Gea, J.; Anto, J.M.; Garcia-Aymerich, J., Dietary modulation of oxidative stress in chronic obstructive pulmonary disease patients. Free Radic. Res., 2010, 44 (11), 1296-1303.
257. Grievink, L.; Smit, H.A.; Ocke, M.C.; van 't Veer, P.; Kromhout, D., Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: The MORGEN study. Thorax, 1998, 53 (3), 166-171.
258. Britton, J.R.; Pavord, I.D.; Richards, K.A.; Knox, A.J.; Wisniewski, A.F.; Lewis, S.A.; Tattersfield, A.E.; Weiss, S.T., Dietary antioxidant vitamin intake and lung function in the general population. Am. J. Respir. Crit. Care Med., 1995, 151 (5), 1383-1387.
259. Hirayama, F.; Lee, A.H.; Oura, A.; Mori, M.; Hiramatsu, N.; Taniguchi, H., Dietary intake of six minerals in relation to the risk of chronic obstructive pulmonary disease. Asia Pac. J. Clin. Nutr., 2010, 19 (4), 572-577.
260. Sargeant, L.A.; Jaeckel, A.; Wareham, N.J., Interaction of vitamin C with the relation between smoking and obstructive airways disease in EPIC Norfolk. European Prospective Investigation into Cancer and Nutrition. Eur. Respir. J., 2000, 16 (3), 397-403.
261. Shahar, E.; Boland, L.L.; Folsom, A.R.; Tockman, M.S.; McGovern, P.G.; Eckfeldt, J.H., Docosahexaenoic acid and smoking-related chronic obstructive pulmonary disease. The Atherosclerosis Risk in Communities Study Investigators. Am. J. Respir. Crit. Care Med., 1999, 159 (6), 1780-1785.
262. Tan, X.L.; Shi, M.; Tang, H.; Han, W.; Spivack, S.D., Candidate dietary phytochemicals modulate expression of phase II enzymes GSTP1 and NQO1 in human lung cells. J. Nutr., 2010, 140 (8), 1404-1410.
263. Arts, I.C.; Hollman, P.C., Polyphenols and disease risk in epidemiologic studies. Am. J. Clin. Nutr., 2005, 81 (1 Suppl), 317S-325S.
264. Knekt, P.; Kumpulainen, J.; Jarvinen, R.; Rissanen, H.; Heliovaara, M.; Reunanen, A.; Hakulinen, T.; Aromaa, A., Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr., 2002, 76 (3), 560-568.
265. Tabak, C.; Arts, I.C.; Smit, H.A.; Heederik, D.; Kromhout, D., Chronic obstructive pulmonary disease and intake of catechins, flavonols, and flavones: The MORGEN Study. Am. J. Respir. Crit. Care Med., 2001, 164 (1), 61-64.
266. Walda, I.C.; Tabak, C.; Smit, H.A.; Rasanen, L.; Fidanza, F.; Menotti, A.; Nissinen, A.; Feskens, E.J.; Kromhout, D., Diet and 20-year chronic obstructive pulmonary disease mortality in middleaged men from three European countries. Eur. J. Clin. Nutr., 2002, 56 (7), 638-643.
267. Santus, P.; Sola, A.; Carlucci, P.; Fumagalli, F.; Di Gennaro, A.; Mondoni, M.; Carnini, C.; Centanni, S.; Sala, A., Lipid peroxidation and 5-lipoxygenase activity in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2005, 171 (8), 838-843.
268. Manna, S.K.; Mukhopadhyay, A.; Aggarwal, B.B., Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol., 2000, 164 (12), 6509-6519.
269. Berge, G.; Ovrebo, S.; Eilertsen, E.; Haugen, A.; Mollerup, S., Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[a]pyrene. Br. J. Cancer, 2004, 91 (7), 1380-1383.
270. Birrell, M.A.; McCluskie, K.; Wong, S.; Donnelly, L.E.; Barnes, P.J.; Belvisi, M.G., Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J., 2005, 19 (7), 840-841.
271. Donnelly, L.E.; Newton, R.; Kennedy, G.E.; Fenwick, P.S.; Leung, R.H.; Ito, K.; Russell, R.E.; Barnes, P.J., Anti-inflammatory effects of resveratrol in lung epithelial cells: Molecular mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol., 2004, 287 (4), L774-783.
272. Knobloch, J.; Sibbing, B.; Jungck, D.; Lin, Y.; Urban, K.; Stoelben, E.; Strauch, J.; Koch, A., Resveratrol impairs the release of steroidresistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther., 2010, 335 (3), 788-798.
273. Pires, K.M.; Valenca, S.S.; Resende, A.C.; Porto, L.C.; Queiroz, E.F.; Moreira, D.D.; de Moura, R.S., Grape skin extract reduced pulmonary oxidative response in mice exposed to cigarette smoke. Med. Sci. Monit., 2011, 17 (8), BR187-195.
274. Siedlinski, M.; Boer, J.M.; Smit, H.A.; Postma, D.S.; Boezen, H.M., Dietary factors and lung function in the general population: Wine and resveratrol intake. Eur. Respir. J., 2011.
275. Biswas, S.K.; McClure, D.; Jimenez, L.A.; Megson, I.L.; Rahman, I., Curcumin induces glutathione biosynthesis and inhibits NFkappaB activation and interleukin-8 release in alveolar epithelial cells: Mechanism of free radical scavenging activity. Antioxid. Redox. Signal, 2005, 7 (1-2), 32-41.
276. Sreejayan Rao, M.N., Curcuminoids as potent inhibitors of lipid peroxidation. J. Pharm. Pharmacol., 1994, 46 (12), 1013-1016.
277. Jobin, C.; Bradham, C.A.; Russo, M.P.; Juma, B.; Narula, A.S.; Brenner, D.A.; Sartor, R.B., Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J. Immunol., 1999, 163 (6), 3474-3483.
278. Anand, P.; Nair, H.B.; Sung, B.; Kunnumakkara, A.B.; Yadav, V.R.; Tekmal, R.R.; Aggarwal, B.B., Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol., 2010, 79 (3), 330-338.
279. Nomura, M.; Ma, W.; Chen, N.; Bode, A.M.; Dong, Z., Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-kappaB activation by tea polyphenols, (-)-epigallocatechin gallate and theaflavins. Carcinogenesis, 2000,
280. Wheeler, D.S.; Catravas, J.D.; Odoms, K.; Denenberg, A.; Malhotra, V.; Wong, H.R., Epigallocatechin-3-gallate, a green teaderived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J. Nutr., 2004, 134 (5), 1039-1044.
281. Qin, S.; Alcorn, J.F.; Craigo, J.K.; Tjoeng, C.; Tarwater, P.M.; Kolls, J.K.; Reinhart, T.A., Epigallocatechin-3-gallate reduces airway inflammation in mice through binding to proinflammatory chemokines and inhibiting inflammatory cell recruitment. J. Immunol., 2011, 186 (6), 3693-3700.
282. March, T.H.; Wilder, J.A.; Esparza, D.C.; Cossey, P.Y.; Blair, L.F.; Herrera, L.K.; McDonald, J.D.; Campen, M.J.; Mauderly, J.L.; Seagrave, J., Modulators of cigarette smoke-induced pulmonary emphysema in A/J mice. Toxicol. Sci., 2006, 92 (2), 545-559.
283. Xu, Y.; Ho, C.T.; Amin, S.G.; Han, C.; Chung, F.L., Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res., 1992, 52 (14), 3875-3879.
284. Fahey, J.W.; Talalay, P., Antioxidant functions of sulforaphane: A potent inducer of Phase II detoxication enzymes. Food Chem. Toxicol., 1999, 37 (9-10), 973-979.
285. Petri, N.; Tannergren, C.; Holst, B.; Mellon, F.A.; Bao, Y.; Plumb, G.W.; Bacon, J.; O'Leary, K.A.; Kroon, P.A.; Knutson, L.; Forsell, P.; Eriksson, T.; Lennernas, H.; Williamson, G., Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab. Dispos., 2003, 31 (6), 805-813.
286. Riedl, M.A.; Saxon, A.; Diaz-Sanchez, D., Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway. Clin. Immunol., 2009, 130 (3), 244-251.
287. Heiss, E.; Herhaus, C.; Klimo, K.; Bartsch, H.; Gerhauser, C., Nuclear factor kappa B is a molecular target for sulforaphanemediated anti-inflammatory mechanisms. J. Biol. Chem., 2001, 276 (34), 32008-32015.
288. Ritz, S.A.; Wan, J.; Diaz-Sanchez, D., Sulforaphane-stimulated phase II enzyme induction inhibits cytokine production by airway epithelial cells stimulated with diesel extract. Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 292 (1), L33-39.
289. Lin, W.; Wu, R.T.; Wu, T.; Khor, T.O.; Wang, H.; Kong, A.N., Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem. Pharmacol., 2008, 76 (8), 967-973.
290. Cheung, K.L.; Khor, T.O.; Kong, A.N., Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation. Pharm. Res., 2009, 26 (1), 224-231.
291. Starrett, W.; Blake, D.J., Sulforaphane inhibits de novo synthesis of IL-8 and MCP-1 in human epithelial cells generated by cigarette smoke extract. J. Immunotoxicol., 2011, 8 (2), 150-158.
292. Harvey, C.J.; Thimmulappa, R.K.; Sethi, S.; Kong, X.; Yarmus, L.; Brown, R.H.; Feller-Kopman, D.; Wise, R.; Biswal, S., Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci. Transl. Med., 2011, 3 (78), 78ra32.
293. Riso, P.; Martini, D.; Moller, P.; Loft, S.; Bonacina, G.; Moro, M.; Porrini, M., DNA damage and repair activity after broccoli intake in young healthy smokers. Mutagenesis, 2010, 25 (6), 595-602.
294. Ganesan, S.; Faris, A.N.; Comstock, A.T.; Chattoraj, S.S.; Chattoraj, A.; Burgess, J.R.; Curtis, J.L.; Martinez, F.J.; Zick, S.; Hershenson, M.B.; Sajjan, U.S., Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression. Respir. Res., 2010, 11, 131.
295. Yang, J.; Wang, L.; Chen, Z.; Shen, Z.Q.; Jin, M.; Wang, X.W.; Zheng, Y.; Qiu, Z.G.; Wang, J.F.; Li, J.W., Antioxidant intervention of smoking-induced lung tumor in mice by vitamin E and quercetin. BMC Cancer, 2008, 8, 383.
296. Gauliard, B.; Grieve, D.; Wilson, R.; Crozier, A.; Jenkins, C.; Mullen, W.D.; Lean, M., The effects of dietary phenolic compounds on cytokine and antioxidant production by A549 cells. J. Med. Food, 2008, 11 (2), 382-384.
297. Nanua, S.; Zick, S.M.; Andrade, J.E.; Sajjan, U.S.; Burgess, J.R.; Lukacs, N.W.; Hershenson, M.B., Quercetin blocks airway epithelial cell chemokine expression. Am. J. Respir. Cell Mol. Biol., 2006, 35 (5), 602-610.
298. Geraets, L.; Moonen, H.J.; Brauers, K.; Wouters, E.F.; Bast, A.; Hageman, G.J., Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose) polymerase-1 in pulmonary epithelial cells. J. Nutr., 2007, 137 (10), 2190-2195.
299. Esanu, V.; Prahoveanu, E.; Crisan, I.; Cioca, A., The effect of an aqueous propolis extract, of rutin and of a rutin-quercetin mixture on experimental influenza virus infection in mice. Virologie, 1981, 32 (3), 213-215.
300. Kumar, P.; Khanna, M.; Srivastava, V.; Tyagi, Y.K.; Raj, H.G.; Ravi, K., Effect of quercetin supplementation on lung antioxidants after experimental influenza virus infection. Exp. Lung Res., 2005, 31 (5), 449-459.
301. Choi, H.J.; Song, J.H.; Kwon, D.H., Quercetin 3-rhamnoside Exerts Antiinfluenza A Virus Activity in Mice. Phytother. Res., 2011.
302. Baldrick, F.R.; Elborn, J.S.; Woodside, J.V.; Treacy, K.; Bradley, J.M.; Patterson, C.C.; Schock, B.C.; Ennis, M.; Young, I.S.; McKinley, M.C., Effect of fruit and vegetable intake on oxidative stress and inflammation in COPD: A RCT. Eur. Respir. J., 2011.
303. Prota, G. Melanins and Melanogenesis. Academic Press: San Diego, California, 1992.
304. Rozanowska, M.; Sarna, T.; Land, E.J.; Truscott, T.G., Free radical scavenging properties of melanin interaction of eu-and pheomelanin models with reducing and oxidising radicals. Free Radic. Biol. Med., 1999, 26 (5-6), 518-525.
305. Borovansky, J., Free radical activity of melanins and related substances: Biochemical and pathobiochemical aspects. Sb. Lek., 1996, 97 (1), 49-70.
306. Shcherba, V.V.; Babitskaia, V.G.; Kurchenko, V.P.; Ikonnikova, N.V.; Kukulianskaia, T.A., Antioxidant properties of fungal melanin pigments. Appl. Biochem. Microbiol., 2000, 36, 491-495.
307. Geremia, E.; Corsaro, C.; Bonomo, R.; Giardinelli, R.; Pappalardo, P.; Vanella, A.; Sichel, G., Eumelanins as free radical trap and superoxide dismutase activity in Amphibia. Comp. Biochem. Physiol., 1984, 79, 67-69.
308. Oettl, K.; Reibnegger, G., Pteridine derivatives as modulators of oxidative stress. Curr. Drug Metab., 2002, 3 (2), 203-209.
309. Reibnegger, G.; Boonpucknavig, V.; Fuchs, D.; Hausen, A.; Schmutzhard, E.; Wachter, H., Urinary neopterin is elevated in patients with malaria. Trans. R. Soc. Trop. Med. Hyg., 1984, 78 (4), 545-546.
310. Wachter, H.; Fuchs, D.; Hausen, A.; Reibnegger, G.; Werner, E.R., Neopterin as marker for activation of cellular immunity: Immunologic basis and clinical application. Adv. Clin. Chem., 1989, 27, 81-141.
311. Boyle, P.H.; Borchert, M.; Davis, A.P.; Heaney, F.M.; Ziegler, I., Modulation of interleukin 2 high affinity binding to human T cells by a pyrimidodiazepine insect metabolite. FEBS Lett., 1993, 334 (3), 309-312.
312. Prior, R.L., Fruits and vegetables in the prevention of cellular oxidative damage. Am. J. Clin. Nutr., 2003, 78 (3 Suppl), 570S-578S.
313. Aviram, M.; Fuhrman, B., Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. Atherosclerosis, 1998, 137 Suppl, S45-50.
314. Bergman, M.; Perelman, A.; Dubinsky, Z.; Grossman, S., Scavenging of reactive oxygen species by a novel glucurinated flavonoid antioxidant isolated and purified from spinach. Phytochemistry, 2003, 62 (5), 753-762.
315. Horvathova, K.; Vachalkova, A.; Novotny, L., Flavonoids as chemoprotective agents in civilization diseases. Neoplasma, 2001, 48 (6), 435-441.
316. Wiseman, S.; Mulder, T.; Rietveld, A., Tea flavonoids: Bioavailability in vivo and effects on cell signaling pathways in vitro. Antioxid. Redox Signal, 2001, 3 (6), 1009-1021.
317. Palozza, P.; Simone, R.; Mele, M.C., Interplay of carotenoids with cigarette smoking: Implications in lung cancer. Curr. Med. Chem., 2008, 15 (9), 844-854.
318. Palozza, P.; Parrone, N.; Catalano, A.; Simone, R., Tomato lycopene and inflammatory cascade: Basic interactions and clinical implications. Curr. Med. Chem., 2010, 17 (23), 2547-2563.
319. Di Mascio, P.; Kaiser, S.; Sies, H., Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch. Biochem. Biophys., 1989, 274 (2), 532-538.
320. Kelkel, M.; Schumacher, M.; Dicato, M.; Diederich, M. Antioxidant and anti-proliferative properties of lycopene. Free Radic. Res., 2011, 45 (8), 925-940.
321. Palozza, P.; Simone, R.; Catalano, A.; Monego, G.; Barini, A.; Mele, M.C.; Parrone, N.; Trombino, S.; Picci, N.; Ranelletti, F.O., Lycopene prevention of oxysterol-induced proinflammatory cytokine cascade in human macrophages: Inhibition of NF-kappaB nuclear binding and increase in PPARgamma expression. J. Nutr. Biochem., 2011, 22 (3), 259-268.
322. Kim, G.Y.; Kim, J.H.; Ahn, S.C.; Lee, H.J.; Moon, D.O.; Lee, C.M.; Park, Y.M., Lycopene suppresses the lipopolysaccharideinduced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB. Immunology, 2004, 113 (2), 203-211.
323. Palozza, P.; Sheriff, A.; Serini, S.; Boninsegna, A.; Maggiano, N.; Ranelletti, F.O.; Calviello, G.; Cittadini, A., Lycopene induces apoptosis in immortalized fibroblasts exposed to tobacco smoke condensate through arresting cell cycle and down-regulating cyclin D1, pAKT and pBad. Apoptosis, 2005, 10 (6), 1445-1456.
324. Graham, D.L.; Carail, M.; Caris-Veyrat, C.; Lowe, G.M., Cigarette smoke and human plasma lycopene depletion. Food Chem. Toxicol., 2010, 48 (8-9), 2413-2420.
325. Simone, R.E.; Russo, M.; Catalano, A.; Monego, G.; Froehlich, K.; Boehm, V.; Palozza, P., Lycopene inhibits NF-kB-mediated IL-8 expression and changes redox and PPARgamma signalling in cigarette smoke-stimulated macrophages. PLoS One, 2011, 6 (5), e19652.
326. Kasagi, S.; Seyama, K.; Mori, H.; Souma, S.; Sato, T.; Akiyoshi, T.; Suganuma, H.; Fukuchi, Y., Tomato juice prevents senescenceaccelerated mouse P1 strain from developing emphysema induced by chronic exposure to tobacco smoke. Am. J. Physiol. Lung Cell Mol. Physiol., 2006, 290 (2), L396-404.
327. Maritz, G.S.; Mutemwa, M.; Kayigire, A.X., Tomato juice protects the lungs of the offspring of female rats exposed to nicotine during gestation and lactation. Pediatr. Pulmonol., 2011, 46 (10), 976-986.
328. Kang, J.; Li, Z.; Wub, T.; Jensen, G.S.; Schauss, A.G.; Wua, X., Anti-oxidant capacities of flavonoid compounds isolated from acai pulp (Euterpe oleracea Mart.). Food Chem., 2010, 122, 610-617.
329. Schauss, A.G.; Wu, X.; Prior, R.L.; Ou, B.; Huang, D.; Owens, J.; Agarwal, A.; Jensen, G.S.; Hart, A.N.; Shanbrom, E., Antioxidant capacity and other bioactivities of the freeze-dried Amazonian palm berry, Euterpe oleraceae mart. (acai). J. Agric. Food Chem., 2006, 54 (22), 8604-8610.
330. Jensen, G.S.; Wu, X.; Patterson, K.M.; Barnes, J.; Carter, S.G.; Scherwitz, L.; Beaman, R.; Endres, J.R.; Schauss, A.G., In vitro and in vivo antioxidant and anti-inflammatory capacities of an antioxidant-rich fruit and berry juice blend. Results of a pilot and randomized, double-blinded, placebo-controlled, crossover study. J Agric Food Chem., 2008, 56 (18), 8326-8333.
331. Sun, X.; Seeberger, J.; Alberico, T.; Wang, C.; Wheeler, C.T.; Schauss, A.G.; Zou, S., Acai palm fruit (Euterpe oleracea Mart.) pulp improves survival of flies on a high fat diet. Exp. Gerontol., 2010, 45, (3), 243-251.
332. Kang, J.; Xie, C.; Li, Z.; Nagarajan, S.; Schauss, A.G.; Wub, T.; Wua, X., Flavonoids from acai (Euterpe oleracea Mart.) pulp and their antioxidant and anti-inflammatory activities. Food Chem., 2011, 128, 152-157.
333. de Moura, R.S.; Pires, K.M.; Santos Ferreira, T.; Lopes, A.A.; Nesi, R.T.; Resende, A.C.; Sousa, P.J.; da Silva, A.J.; Porto, L.C.; Valenca, S.S., Addition of acai (Euterpe oleracea) to cigarettes has a protective effect against emphysema in mice. Food Chem. Toxicol., 2011, 49 (4), 855-863.
334. Hougee, S.; Hartog, A.; Sanders, A.; Graus, Y.M.; Hoijer, M.A.; Garssen, J.; van den Berg, W.B.; van Beuningen, H.M.; Smit, H.F., Oral administration of the NADPH-oxidase inhibitor apocynin partially restores diminished cartilage proteoglycan synthesis and reduces inflammation in mice. Eur. J. Pharmacol., 2006, 531 (1-3), 264-269.
335. Johnson, D.K.; Schillinger, K.J.; Kwait, D.M.; Hughes, C.V.; McNamara, E.J.; Ishmael, F.; O'Donnell, R.W.; Chang, M.M.; Hogg, M.G.; Dordick, J.S.; Santhanam, L.; Ziegler, L.M.; Holland, J.A., Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium, 2002, 9 (3), 191-203.
336. Peters, E.A.; Hiltermann, J.T.; Stolk, J., Effect of apocynin on ozone-induced airway hyperresponsiveness to methacholine in asthmatics. Free Radic. Biol. Med., 2001, 31 (11), 1442-1447.
337. Muijsers, R.B.; van Den Worm, E.; Folkerts, G.; Beukelman, C.J.; Koster, A.S.; Postma, D.S.; Nijkamp, F.P., Apocynin inhibits peroxynitrite formation by murine macrophages. Br. J. Pharmacol., 2000, 130 (4), 932-936.
338. Sadeghi-Hashjin, G.; Folkerts, G.; Henricks, P.A.; Verheyen, A.K.; van der Linde, H.J.; van Ark, I.; Coene, A.; Nijkamp, F.P., Peroxynitrite induces airway hyperresponsiveness in guinea pigs in vitro and in vivo. Am. J. Respir. Crit. Care Med., 1996, 153 (5), 1697-1701.
339. Gao, X.P.; Standiford, T.J.; Rahman, A.; Newstead, M.; Holland, S.M.; Dinauer, M.C.; Liu, Q.H.; Malik, A.B., Role of NADPH oxidase in the mechanism of lung neutrophil sequestration and microvessel injury induced by Gram-negative sepsis: Studies in p47phox-/-and gp91phox-/-mice. J. Immunol., 2002, 168 (8), 3974-3982.
340. Gao, X.P.; Zhu, X.; Fu, J.; Liu, Q.; Frey, R.S.; Malik, A.B., Blockade of class IA phosphoinositide 3-kinase in neutrophils prevents NADPH oxidase activation-and adhesion-dependent inflammation. J. Biol. Chem., 2007, 282 (9), 6116-6125.
341. Wang, Y.H.; Shen, Y.C.; Liao, J.F.; Lee, C.H.; Chou, C.Y.; Liou, K.T.; Chou, Y.C., Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice. Br. J. Pharmacol., 2008, 154 (6), 1327-1338.
342. Lapperre, T.S.; Jimenez, L.A.; Antonicelli, F.; Drost, E.M.; Hiemstra, P.S.; Stolk, J.; MacNee, W.; Rahman, I., Apocynin increases glutathione synthesis and activates AP-1 in alveolar epithelial cells. FEBS Lett., 1999, 443 (2), 235-239.
343. Kim, S.Y.; Moon, K.A.; Jo, H.Y.; Jeong, S.; Seon, S.H.; Jung, E.; Cho, Y.S.; Chun, E.; Lee, K.Y., Anti-inflammatory effects of apocynin, an inhibitor of NADPH oxidase, in airway inflammation. Immunol. Cell Biol., 2011.
344. Impellizzeri, D.; Esposito, E.; Mazzon, E.; Paterniti, I.; Di Paola, R.; Bramanti, P.; Cuzzocrea, S., Effect of apocynin, a NADPH oxidase inhibitor, on acute lung inflammation. Biochem. Pharmacol., 2011, 81 (5), 636-648.
345. Schwartz, J., Role of polyunsaturated fatty acids in lung disease. Am. J. Clin. Nutr., 2000, 71, (1 Suppl), 393S-396S.
346. Rein, P.; Saely, C.H.; Aczel, S.; Patsch, B.; Drexel, H., Omega-3 fatty acids significantly reduce postprandial triglyceridemia in male smokers: A pilot study. Nutr. Metab. Cardiovasc. Dis., 2009, 19 (2), e3-4.
347. Puri, B.K.; Treasaden, I.H.; Cocchi, M.; Tsaluchidu, S.; Tonello, L.; Ross, B.M., A comparison of oxidative stress in smokers and non-smokers: An in vivo human quantitative study of n-3 lipid peroxidation. BMC Psychiatry, 2008, 8 Suppl 1, S4.
348. Ohsawa, M.; Itai, K.; Onoda, T.; Tanno, K.; Sasaki, S.; Nakamura, M.; Ogawa, A.; Sakata, K.; Kawamura, K.; Kuribayashi, T.; Yoshida, Y.; Okayama, A., Dietary intake of n-3 polyunsaturated fatty acids is inversely associated with CRP levels, especially among male smokers. Atherosclerosis, 2008, 201 (1), 184-191.
349. de Batlle, J.; Sauleda, J.; Balcells, E.; Gomez, F.P.; Mendez, M.; Rodriguez, E.; Barreiro, E.; Ferrer, J.J.; Romieu, I.; Gea, J.; Anto, J.M.; Garcia-Aymerich, J., Association between Omega3 and Omega6 fatty acid intakes and serum inflammatory markers in COPD. J. Nutr. Biochem., 2011.
350. Fasano, E.; Serini, S.; Piccioni, E.; Innocenti, I.; Calviello, G., Chemoprevention of lung pathologies by dietary n-3 polyunsaturated fatty acids. Curr. Med. Chem., 2010, 17 (29), 3358-3376.
351. McKeever, T.M.; Lewis, S.A.; Cassano, P.A.; Ocke, M.; Burney, P.; Britton, J.; Smit, H.A., The relation between dietary intake of individual fatty acids, FEV1 and respiratory disease in Dutch adults. Thorax, 2008, 63 (3), 208-214.
352. Shahar, E.; Folsom, A.R.; Melnick, S.L.; Tockman, M.S.; Comstock, G.W.; Gennaro, V.; Higgins, M.W.; Sorlie, P.D.; Ko, W.J.; Szklo, M., Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators. N. Engl. J. Med., 1994, 331 (4), 228-233.
353. Mas, E.; Woodman, R.J.; Burke, V.; Puddey, I.B.; Beilin, L.J.; Durand, T.; Mori, T.A., The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebocontrolled interventions. Free Radic. Res., 2010, 44 (9), 983-990.
354. Wu-Wang, C.Y.; Wang, S.L.; Lim, C.; Milles, M.; Slomiany, A.; Slomiany, B.L., Cigarette smoking reduces human salivary eicosanoids. Prostaglandins. Leukot. Essent. Fatty Acids, 1992, 47 (2), 101-104.
355. Serhan, C.N.; Chiang, N.; Van Dyke, T.E., Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol., 2008, 8 (5), 349-361.
356. Serhan, C.N.; Yang, R.; Martinod, K.; Kasuga, K.; Pillai, P.S.; Porter, T.F.; Oh, S.F.; Spite, M., Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med., 2009, 206 (1), 15-23.
357. Serhan, C.N.; Petasis, N.A., Resolvins and protectins in inflammation resolution. Chem. Rev., 2011, 111 (10), 5922-5943.
358. Levy, B.D.; Kohli, P.; Gotlinger, K.; Haworth, O.; Hong, S.; Kazani, S.; Israel, E.; Haley, K.J.; Serhan, C.N., Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol., 2007, 178 (1), 496-502.
359. Arita, M.; Bianchini, F.; Aliberti, J.; Sher, A.; Chiang, N.; Hong, S.; Yang, R.; Petasis, N.A.; Serhan, C.N., Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med., 2005, 201 (5), 713-722.
360. Haworth, O.; Cernadas, M.; Yang, R.; Serhan, C.N.; Levy, B.D., Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol., 2008, 9 (8), 873-879.
361. Spite, M.; Summers, L.; Porter, T.F.; Srivastava, S.; Bhatnagar, A.; Serhan, C.N., Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. Br. J. Pharmacol., 2009, 158 (4), 1062-1073.
362. Serhan, C.N., The resolution of inflammation: The devil in the flask and in the details. FASEB J., 2011, 25 (5), 1441-1448.
363. Spite, M.; Serhan, C.N., Novel lipid mediators promote resolution of acute inflammation: Impact of aspirin and statins. Circ. Res., 2010, 107 (10), 1170-1184.
364. Xaubet, A.; Roca-Ferrer, J.; Pujols, L.; Ramirez, J.; Mullol, J.; Marin-Arguedas, A.; Torrego, A.; Gimferrer, J.M.; Picado, C., Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. Sarcoidosis. Vasc. Diffuse Lung Dis., 2004, 21 (1), 35-42.
365. Chen, Y.; Chen, P.; Hanaoka, M.; Droma, Y.; Kubo, K., Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology, 2008, 13 (7), 1014-1021.
366. Lassen, N.; Bateman, J.B.; Estey, T.; Kuszak, J.R.; Nees, D.W.; Piatigorsky, J.; Duester, G.; Day, B.J.; Huang, J.; Hines, L.M.; Vasiliou, V., Multiple and additive functions of ALDH3A1 and ALDH1A1: Cataract phenotype and ocular oxidative damage in Aldh3a1(-/-)/Aldh1a1(-/-) knock-out mice. J. Biol. Chem., 2007, 282 (35), 25668-25676.
367. Hansdottir, S.; Monick, M.M.; Lovan, N.; Powers, L.S.; Hunninghake, G.W., Smoking Disrupts Vitamin D Metabolism In The Lungs. Am. J. Respir. Crit. Care Med., 2010, 181, (1-MeetingAbstracts), A1425.
368. Holick, M.F., Vitamin D deficiency. N. Engl. J. Med., 2007, 357 (3), 266-281.
369. Sundar, I.K.; Hwang, J.W.; Wu, S.; Sun, J.; Rahman, I., Deletion of vitamin D receptor leads to premature emphysema/COPD by increased matrix metalloproteinases and lymphoid aggregates formation. Biochem. Biophys. Res. Commun., 2011, 406 (1), 127-133.
370. Kunisaki, K.M.; Niewoehner, D.E.; Connett, J.E., Vitamin D Levels and Risk of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study. Am. J. Respir. Crit. Care Med., 2011.
371. Kirkham, P.; Rahman, I., Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol. Ther., 2006, 111 (2), 476-494.
372. Allard, J.P.; Royall, D.; Kurian, R.; Muggli, R.; Jeejeebhoy, K.N., Effects of beta-carotene supplementation on lipid peroxidation in humans. Am. J. Clin. Nutr., 1994, 59 (4), 884-890.